- βAI-powered CGM algorithms can forecast low blood sugar events earlier than current trend arrows, giving patients more response time
- βPersonalized glucose prediction models learn individual patterns rather than relying on population averages
- βImproved prediction accuracy may reduce hypoglycemia fear and diabetes-related anxiety, benefiting mental health alongside physical outcomes
| Country | UK |
| Journal | Diabetes technology & therapeutics |
| Year | 2025 |
| Authors | Hussain, Polonsky, Scibilia |
| PMID | 40441551 |
A study from the UK, led by researchers at King's College London and Guy's & St Thomas' NHS Foundation Trust, examines how artificial intelligence could transform the way continuous glucose monitors (CGMs) warn people with Type 1 diabetes about dangerous low blood sugar episodes β potentially before they even begin.
What the Research Is About
Most CGM devices today show a "trend arrow" β a simple up or down indicator telling you which direction your blood sugar is heading. While helpful, these arrows only reflect what's happening right now. The UK research team argues this isn't enough. Their article, published in Diabetes Technology & Therapeutics (2025), reviews how AI-driven glucose prediction algorithms can forecast blood sugar levels over longer time windows, giving patients critical extra minutes β or even hours β to act.
Why Hypoglycemia Is Still a Crisis
Low blood sugar (hypoglycemia) remains one of the most dangerous and emotionally draining aspects of living with Type 1 diabetes. A blood sugar reading below 70 mg/dL (3.9 mmol/L) is considered low by both US and international standards, while readings below 54 mg/dL (3.0 mmol/L) signal a serious, potentially life-threatening event. The UK authors note that fear of hypoglycemia drives anxiety, disrupted sleep, and can actually prevent patients from reaching their glucose goals β a vicious cycle familiar to millions of Americans with Type 1 diabetes.
Current CGM systems use threshold-based alarms β your device buzzes when you already are at 70 mg/dL. AI prediction moves the warning earlier in the timeline, alerting you that you will be at 70 mg/dL in 20, 30, or 60 minutes if nothing changes.
What AI Adds Beyond the Arrow
The researchers describe AI models that can analyze patterns in your personal glucose history, meal timing, activity, and insulin behavior to generate individualized forecasts. This is meaningfully different from population-based algorithms. Rather than predicting what happens to the "average" diabetic, these systems learn your patterns β because a 45-minute morning walk affects one person's blood sugar very differently than another's.
The UK Perspective and What Makes It Relevant for Americans
The UK's National Health Service manages one of the world's largest centralized diabetes populations, giving British researchers access to broad, real-world CGM datasets. Their findings carry weight because they reflect diverse, everyday use β not just controlled clinical trial conditions. The American Diabetes Association (ADA) currently recommends CGM use for all people with Type 1 diabetes, and Time in Range (the percentage of time blood sugar stays between 70β180 mg/dL) is a core US treatment target. AI prediction tools that reduce time below 70 mg/dL would directly improve this metric for American patients.
Why This Matters for US Patients
- Earlier warnings mean more options. An extra 30β60 minutes of warning before a low gives you time to eat, adjust insulin, or slow physical activity β rather than scrambling mid-crisis.
- Mental health benefits are real. The authors specifically highlight the psychosocial burden of hypoglycemia fear. Smarter alarms that reduce false alerts and improve accuracy could meaningfully lower diabetes-related anxiety.
- US device makers are already moving this direction. Dexcom, Abbott, and Medtronic all have AI-adjacent features in development or on the market. Understanding the science helps patients ask better questions about upcoming device upgrades.
- Insurance and access implications. As AI-powered CGM features become standard, US advocacy groups will need outcome data β like this research β to support insurance coverage arguments.
The Bottom Line
The trend arrow on your CGM is a starting point, not a finish line. This UK research makes a compelling case that AI-supported glucose forecasting is the next meaningful leap forward β one that could reduce dangerous lows, ease emotional burden, and give people with Type 1 diabetes something they rarely get enough of: time to respond.
Source: Hussain, Polonsky, Scibilia. "Beyond the Trend Arrow: Potential Value of Artificial Intelligence-Supported Glucose Predictions for People with Type 1 Diabetes Using Continuous Glucose Monitoring Systems." Diabetes Technology & Therapeutics, 2025. DOI: 10.1089/dia.2025.0293 | PMID: 40441551